{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:09:10Z","timestamp":1772017750138,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40271-025-00789-9","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T17:30:21Z","timestamp":1764005421000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Insights on Acne Hyperpigmentation, Trifarotene, and Skincare: 6-Month, LEAP Phase 4 Qualitative Exit Interview Findings"],"prefix":"10.1007","volume":"19","author":[{"given":"Carla","family":"Dias-Barbosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Philippe","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Puelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"1","key":"789_CR1","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.1038\/s41598-020-62715-3","volume":"10","author":"AHS Heng","year":"2020","unstructured":"Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754.","journal-title":"Sci Rep"},{"issue":"6","key":"789_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.mpmed.2017.03.003","volume":"45","author":"A Mahto","year":"2017","unstructured":"Mahto A. Acne vulgaris. Medicine. 2017;45(6):386\u20139.","journal-title":"Medicine"},{"issue":"7","key":"789_CR3","first-page":"20","volume":"3","author":"EC Davis","year":"2010","unstructured":"Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20\u201331.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"789_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/bjd\/ljad026","volume":"188","author":"B Schuster","year":"2023","unstructured":"Schuster B, Gallinger J, Philipp-Dormston WG, Vasel M, Layton AM. Less confident, successful and happy: patients with post-acne hyperpigmentation are stigmatized. Br J Dermatol. 2023;188(5):682\u20134.","journal-title":"Br J Dermatol"},{"issue":"5","key":"789_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/jdv.15419","volume":"33","author":"B Dreno","year":"2019","unstructured":"Dreno B, Bordet C, Seite S, Taieb C. Acne relapses: impact on quality of life and productivity. J Eur Acad Dermatol Venereol. 2019;33(5):937\u201343.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"789_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4103\/0019-5154.190102","volume":"61","author":"N Hazarika","year":"2016","unstructured":"Hazarika N, Archana M. The psychosocial impact of acne vulgaris. Indian J Dermatol. 2016;61(5):515\u201320.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"789_CR7","first-page":"121","volume":"98","author":"A Hosthota","year":"2016","unstructured":"Hosthota A, Bondade S, Basavaraja V. Impact of acne vulgaris on quality of life and self-esteem. Cutis. 2016;98(2):121\u20134.","journal-title":"Cutis"},{"issue":"5","key":"789_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1046\/j.1365-2133.1998.02511.x","volume":"139","author":"MA Gupta","year":"1998","unstructured":"Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846\u201350.","journal-title":"Br J Dermatol"},{"issue":"6","key":"789_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/ijd.17189","volume":"63","author":"A Alexis","year":"2024","unstructured":"Alexis A, Del Rosso JQ, Forman S, Martorell A, Browning J, Laquer V, et al. Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. 2024;63(6):806\u201315.","journal-title":"Int J Dermatol"},{"issue":"9813","key":"789_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","volume":"379","author":"HC Williams","year":"2012","unstructured":"Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361\u201372.","journal-title":"Lancet"},{"key":"789_CR11","unstructured":"Lawrence E, KM AA. Postinflammatory hyperpigmentation. StatPearls. 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32644576."},{"issue":"5","key":"789_CR12","doi-asserted-by":"publisher","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","volume":"90","author":"RV Reynolds","year":"2024","unstructured":"Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-.e30.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"789_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/12034754211035091","volume":"26","author":"M Motamedi","year":"2022","unstructured":"Motamedi M, Chehade A, Sanghera R, Grewal P. A clinician\u2019s guide to topical retinoids. J Cutan Med Surg. 2022;26(1):71\u20138.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"789_CR14","first-page":"s6","volume":"17","author":"LK Hoffman","year":"2018","unstructured":"Hoffman LK, Bhatia N, Zeichner J, Kircik LH. Topical vehicle formulations in the treatment of acne. J Drugs Dermatol. 2018;17(6):s6\u201310.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"789_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","volume":"80","author":"J Tan","year":"2019","unstructured":"Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 \u03bcg\/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"789_CR16","first-page":"442","volume":"179","author":"J Aubert","year":"2018","unstructured":"Aubert J, Piwnica D, Bertino B, Blanchet-R\u00e9thor\u00e9 S, Carlavan I, D\u00e9ret S, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-\u03b3 agonist trifarotene. Br J Dermatol. 2018;179(2):442\u201356.","journal-title":"Br J Dermatol"},{"issue":"2","key":"789_CR17","first-page":"231","volume":"179","author":"DMW Balak","year":"2018","unstructured":"Balak DMW. Topical trifarotene: a new retinoid. Br J Dermatol. 2018;179(2):231\u20132.","journal-title":"Br J Dermatol"},{"issue":"12","key":"789_CR18","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s13555-023-01042-7","volume":"13","author":"S Schleicher","year":"2023","unstructured":"Schleicher S, Moore A, Rafal E, Gagne-Henley A, Johnson SM, Dhawan S, et al. Trifarotene reduces risk for atrophic acne scars: results from a phase 4 controlled study. Dermatol Ther (Heidelb). 2023;13(12):3085\u201396.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"789_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, et al. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3(1):16.","journal-title":"J Patient Rep Outcomes"},{"key":"789_CR20","unstructured":"FDA. Patient-focused drug development: methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders. Center for Biologics Evaluation and Research (CBER). US Department of Health and Human Services; 2022. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients."},{"issue":"1","key":"789_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13023-018-0835-1","volume":"13","author":"M Bharmal","year":"2018","unstructured":"Bharmal M, Guillemin I, Marrel A, Arnould B, Lambert J, Hennessy M, et al. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. Orphanet J Rare Dis. 2018;13(1):95.","journal-title":"Orphanet J Rare Dis"},{"key":"789_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/16094069231205789","volume":"22","author":"M Naeem","year":"2023","unstructured":"Naeem M, Ozuem W, Howell K, Ranfagni S. A step-by-step process of thematic analysis to develop a conceptual model in qualitative research. Int J Qual Methods. 2023;22:16094069231205789.","journal-title":"Int J Qual Methods"},{"issue":"5","key":"789_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS ONE. 2020;15(5):e0232076.","journal-title":"PLoS ONE"},{"issue":"4","key":"789_CR24","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907.","journal-title":"Qual Quant"},{"issue":"6","key":"789_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40257-021-00633-4","volume":"22","author":"N Elbuluk","year":"2021","unstructured":"Elbuluk N, Grimes P, Chien A, Hamzavi I, Alexis A, Taylor S, et al. The pathogenesis and management of acne-induced post-inflammatory hyperpigmentation. Am J Clin Dermatol. 2021;22(6):829\u201336.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"789_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/1346-8138.13263","volume":"43","author":"F Abad-Casintahan","year":"2016","unstructured":"Abad-Casintahan F, Chow SK, Goh CL, Kubba R, Hayashi N, Noppakun N, et al. Frequency and characteristics of acne-related post-inflammatory hyperpigmentation. J Dermatol. 2016;43(7):826\u20138.","journal-title":"J Dermatol"},{"issue":"1","key":"789_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40257-021-00643-2","volume":"23","author":"VD Callender","year":"2022","unstructured":"Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, Stein Gold L, Guenin E. Effects of topical retinoids on acne and post-inflammatory hyperpigmentation in patients with skin of color: a clinical review and implications for practice. Am J Clin Dermatol. 2022;23(1):69\u201381.","journal-title":"Am J Clin Dermatol"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00789-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:11:37Z","timestamp":1772014297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00789-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00789-9","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KC, JPY, JP, and RC are employees of Galderma. CDB and NT are employees of Evidera, which was funded by Galderma to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data supporting the findings of this study are available from Evidera. Access to the data may be subject to certain restrictions due to privacy concerns with the sponsor; please contact the corresponding author for further information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"CDB, JPY, RC, and JP contributed to the conception of the study, and CDB, NT, RC, and JP helped develop the methodology. NT managed software. CDB and NT were in charge of the formal analysis, investigation, and data curation. CDB supervised the project, which was administered by NT and KC. KC and RC were responsible for acquiring funding. CDB, NT, KC, JPY, JP, and RC reviewed and edited the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}